Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A for myalgia and myofascial pain in temporomandibular disorders
2023-504033-44-00Phase 3Authorised
- Sponsor
- Folktandvården Stockholm
- Start
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in temporomandibular disorder (TMD), myalgia and chronic myofascial pain (CMP), sponsored by Folktandvården Stockholm. Primary endpoint: Change in pain intensity. Planned start Feb 2024; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
temporomandibular disorder (TMD)myalgiachronic myofascial pain (CMP)
Beyond the preview
Go deeper on 2023-504033-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504033-44-00.